Clene (CLNN) Stock Price, News & Analysis

Company Overview

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

Key Stats

• Today's Range: $4.27 to $4.45
• 50-Day Range: $3.88 to $6.38
• 52-Week Range: $3.82 to $12.00
• Volume: 45,009 shs
• Average Volume: 74,741 shs
• Market Capitalization: $36.20 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $55.25
• Consensus Rating: Buy

Clene Stock Analysis - MarketRank™

Clene scored higher than 78% of companies evaluated by MarketBeat, and ranked 254th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Clene has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Clene has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Clene are expected to grow in the coming year, from ($5.19) to ($4.15) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Clene is -0.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Clene is -0.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Clene has a P/B Ratio of 2.06. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.14% of the float of Clene has been sold short.

Short Interest Ratio / Days to Cover

Clene has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Clene has recently decreased by 32.54%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Clene does not currently pay a dividend.

Dividend Growth

Clene does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.14% of the float of Clene has been sold short.

Short Interest Ratio / Days to Cover

Clene has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Clene has recently decreased by 32.54%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.62

News Sentiment

Clene has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Clene this week, compared to 2 articles on an average week.

Search Interest

10 people have searched for CLNN on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.

MarketBeat Follows

3 people have added Clene to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Clene insiders have bought more of their company's stock than they have sold. Specifically, they have bought $535,890.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

25.10% of the stock of Clene is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 23.28% of the stock of Clene is held by institutions.

CLNN Stock Analysis - Frequently Asked Questions

How have CLNN shares performed this year?

Clene's stock was trading at $5.9320 on January 1st, 2024. Since then, CLNN shares have decreased by 27.3% and is now trading at $4.31.
View the best growth stocks for 2024 here.

How were Clene's earnings last quarter?

Clene Inc. (NASDAQ:CLNN) announced its quarterly earnings results on Wednesday, August, 7th. The company reported ($1.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.60) by $0.54. The company earned $0.09 million during the quarter, compared to analyst estimates of $0.10 million. Clene had a negative trailing twelve-month return on equity of 1,106.30% and a negative net margin of 8,556.77%.

When did Clene's stock split?

Clene's stock reverse split before market open on Thursday, July 11th 2024. The 1-20 reverse split was announced on Thursday, July 11th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 11th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Who are Clene's major shareholders?

Clene's top institutional investors include Lunt Capital Management Inc. (0.43%) and Castleview Partners LLC (0.19%). Insiders that own company stock include General Resonance Llc, David J Matlin, John Henry Stevens, Mark Mortenson, Jonathon Gay, Alison Mosca, Robert Dee Etherington and Robert Glanzman.
View institutional ownership trends.

How do I buy shares of Clene?

Shares of CLNN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Clene own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Clene investors own include Waste Connections (WCN), AUO (AUOTY), Voyager Therapeutics (VYGR), American Water Works (AWK), DiamondRock Hospitality (DRH), The RMR Group (RMR) and iShares Micro-Cap ETF (IWC).

Company Calendar

• Last Earnings: 8/07/2024
• Today: 12/18/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CLNN
• CUSIP: N/A
• CIK: 1822791
• Web: clene.com
• Phone: 801-676-9695
• Fax: N/A
• Employees: 100
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $55.25
• High Stock Price Target: $84.00
• Low Stock Price Target: $23.00
• Potential Upside/Downside: +1,178.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.20
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($5.28)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-49,500,000.00
• Net Margins: -8,556.77%
• Pretax Margin: -8,556.77%
• Return on Equity: -1,106.30%
• Return on Assets: -85.11%

Debt

• Debt-to-Equity Ratio: 1.66
• Current Ratio: 0.83
• Quick Ratio: 0.82

Sales & Book Value

• Annual Sales: $421,000.00
• Price / Sales: 85.78
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.09 per share
• Price / Book: 2.07

Miscellaneous

• Outstanding Shares: 8,360,000
• Free Float: 6,262,000
• Market Cap: $36.12 million
• Optionable: Optionable
• Beta: 0.32